Market Report
US close: Nasdaq drops 3% as AI stocks hammered by DeepSeek news
A sell-off in the tech sector drove the S&P 500 and Nasdaq firmly into the red on Monday, as concerns about a bubble in the US artificial intelligence industry hammered market sentiment.
Broker tips: Inchcape, Energean, British American Tobacco, WH Smith
Last week's sell-off in Inchcape's shares was overdone, according to analysts at Citi, which retained a 'buy' rating on the stock.
London close: Stocks mixed as investors look to Fed
London stocks ended Monday with a mixed performance as investors braced for a week dominated by key interest rate decisions and major corporate earnings.
Director dealings: Watkin Jones chairman raises stake
Watkin Jones revealed on Monday that chairman Alan Giddins had acquired 148,000 ordinary shares in the AIM-listed residential property management firm.
High street sale would remove a reason not to buy WH Smith shares, says RBC
A potential sale of WH Smith’s high street business would remove a reason not to buy the shares and make it a more attractive "pure-play", RBC Capital Markets said in a note on Monday.
US open: Stocks lower amid AI rout
Wall Street stocks were lower at the open on Monday amid concerns that the artificial intelligence bubble may be about to pop.
Ondine Biomedical gets $4m investment from HCA Healthcare subsidiary
Ondine Biomedical announced a $4m equity investment from hInsight-NX, a subsidiary of US medical facilities giant HCA Healthcare, on Monday, extending its cash runway through to the fourth quarter.
Mind Gym appoints US chief commercial officer
Mind Gym announced the appointment of Adam Maude as chief commercial officer for its US operations on Monday.
UBS upgrades BAT to 'buy', shares spark
UBS upgraded British American Tobacco on Monday to ‘buy’ from ‘neutral’, hiked the price target to 3,900p from 3,000p and made the stock its ‘top pick’.
FTSE 100 movers: BAT boosted by upgrade; miners in the red
London’s FTSE 100 was up 0. 1% at 8,509. 57 in afternoon trade on Monday.
Berenberg lowers target price on Energean
Analysts at Berenberg lowered their target price on exploration and production firm Energean from 1,045. 0p to 940. 0p on Monday following the group's recent FY trading update.
FTSE 250 movers: Diversified gains on Maverick deal; Tech stock stumble
FTSE 250 (MCX) 20,350. 09 -0. 82% .
London midday: Stocks stay down after weak China data
London stocks remained in negative territory by midday on Monday as investors turned their attention to a pivotal week featuring interest rate decisions from the US Federal Reserve and the European Central Bank, alongside earnings reports from several major US technology companies.
Corcel confirms intervention work to restart in Angola block
Corcel announced on Monday that intervention activities at the Tobias-13 and Tobias-14 wells in Angola's block KON-11 would soon restart.
Rome Resources says operations unaffected by Goma unrest
Rome Resources confirmed on Monday that its exploration activities in the Democratic Republic of Congo remained unaffected by recent unrest in the city of Goma.
Safestay enters strategic tech partnership with Cloudbeds
Safestay announced a strategic partnership with hospitality management platform Cloudbeds on Monday, as part of its ‘platform for growth’ strategy aimed at enhancing guest experience and driving operational efficiency.
United Oil issues shares to settle legacy Rockhopper liability
United Oil & Gas announced the final settlement of an outstanding legacy liability with Rockhopper Exploration on Monday, through the issue of 59,523,810 new shares at a price of 0. 1p each.
Shield Therapeutics appoints Anders Lundstrom as permanent CEO
Shield Therapeutics announced the appointment of Anders Lundstrom as its permanent chief executive officer on Monday, effective 1 February.
US pre-open: Futures sharply lower on Chinese AI news
Wall Street futures were sharply lower ahead of the bell on Monday amid concerns that the artificial intelligence bubble may be about to pop.
hVIVO signs LOI to conduct pivotal whooping cough study
hVIVO announced on Monday that it has signed a letter of intent with ILiAD Biotechnologies to conduct a pivotal phase three human challenge trial for ILiAD's lead whooping cough vaccine candidate, BPZE1.